Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
6
IKNA Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
-0.82%
Day range:
$1.56 - $1.62
52-week range:
$1.22 - $2.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.20x
P/B ratio:
0.56x
Volume:
207.2K
Avg. volume:
105.6K
1-year change:
-20%
Market cap:
$75.3M
Revenue:
$9.2M
EPS (TTM):
-$1.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IKNA
Ikena Oncology
|
-- | -$0.28 | -100% | -57.5% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
MNOV
MediciNova
|
-- | -- | -100% | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IKNA
Ikena Oncology
|
$1.56 | -- | $75.3M | -- | $0.00 | 0% | 8.20x |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
MNOV
MediciNova
|
$2.15 | -- | $105.4M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.14 | $100.00 | $3.2M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IKNA
Ikena Oncology
|
-- | 2.770 | -- | -- |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
MNOV
MediciNova
|
-- | 2.202 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IKNA
Ikena Oncology
|
-- | -$11.6M | -- | -- | -- | -$8.9M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
MNOV
MediciNova
|
-- | -$3.3M | -- | -- | -- | -$2M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
Ikena Oncology vs. Competitors
-
Which has Higher Returns IKNA or IBIO?
iBio has a net margin of -- compared to Ikena Oncology's net margin of -4444.57%. Ikena Oncology's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital IKNAIkena Oncology-- -$0.21 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About IKNA or IBIO?
Ikena Oncology has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Ikena Oncology has higher upside potential than iBio, analysts believe Ikena Oncology is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings IKNAIkena Oncology0 0 0 IBIOiBio0 0 0 -
Is IKNA or IBIO More Risky?
Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock IKNA or IBIO?
Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IKNA or IBIO?
Ikena Oncology quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Ikena Oncology's net income of -$10.2M is lower than iBio's net income of -$4M. Notably, Ikena Oncology's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 8.20x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IKNAIkena Oncology8.20x -- -- -$10.2M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns IKNA or MNOV?
MediciNova has a net margin of -- compared to Ikena Oncology's net margin of --. Ikena Oncology's return on equity of -- beat MediciNova's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IKNAIkena Oncology-- -$0.21 -- MNOVMediciNova-- -$0.06 -- -
What do Analysts Say About IKNA or MNOV?
Ikena Oncology has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand MediciNova has an analysts' consensus of -- which suggests that it could grow by 287.6%. Given that MediciNova has higher upside potential than Ikena Oncology, analysts believe MediciNova is more attractive than Ikena Oncology.
Company Buy Ratings Hold Ratings Sell Ratings IKNAIkena Oncology0 0 0 MNOVMediciNova0 0 0 -
Is IKNA or MNOV More Risky?
Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MediciNova has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.569%.
-
Which is a Better Dividend Stock IKNA or MNOV?
Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. MediciNova pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IKNA or MNOV?
Ikena Oncology quarterly revenues are --, which are smaller than MediciNova quarterly revenues of --. Ikena Oncology's net income of -$10.2M is lower than MediciNova's net income of -$2.9M. Notably, Ikena Oncology's price-to-earnings ratio is -- while MediciNova's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 8.20x versus -- for MediciNova. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IKNAIkena Oncology8.20x -- -- -$10.2M MNOVMediciNova-- -- -- -$2.9M
-
Which has Higher Returns IKNA or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Ikena Oncology's net margin of -49.65%. Ikena Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IKNAIkena Oncology-- -$0.21 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About IKNA or NBY?
Ikena Oncology has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Ikena Oncology, analysts believe NovaBay Pharmaceuticals is more attractive than Ikena Oncology.
Company Buy Ratings Hold Ratings Sell Ratings IKNAIkena Oncology0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is IKNA or NBY More Risky?
Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock IKNA or NBY?
Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IKNA or NBY?
Ikena Oncology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ikena Oncology's net income of -$10.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ikena Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 8.20x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IKNAIkena Oncology8.20x -- -- -$10.2M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns IKNA or PTN?
Palatin Technologies has a net margin of -- compared to Ikena Oncology's net margin of -2357.27%. Ikena Oncology's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IKNAIkena Oncology-- -$0.21 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About IKNA or PTN?
Ikena Oncology has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Ikena Oncology, analysts believe Palatin Technologies is more attractive than Ikena Oncology.
Company Buy Ratings Hold Ratings Sell Ratings IKNAIkena Oncology0 0 0 PTNPalatin Technologies0 0 0 -
Is IKNA or PTN More Risky?
Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock IKNA or PTN?
Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IKNA or PTN?
Ikena Oncology quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Ikena Oncology's net income of -$10.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 8.20x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IKNAIkena Oncology8.20x -- -- -$10.2M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns IKNA or TOVX?
Theriva Biologics has a net margin of -- compared to Ikena Oncology's net margin of --. Ikena Oncology's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IKNAIkena Oncology-- -$0.21 -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About IKNA or TOVX?
Ikena Oncology has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than Ikena Oncology, analysts believe Theriva Biologics is more attractive than Ikena Oncology.
Company Buy Ratings Hold Ratings Sell Ratings IKNAIkena Oncology0 0 0 TOVXTheriva Biologics1 0 0 -
Is IKNA or TOVX More Risky?
Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock IKNA or TOVX?
Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IKNA or TOVX?
Ikena Oncology quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Ikena Oncology's net income of -$10.2M is lower than Theriva Biologics's net income of -$7.7M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 8.20x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IKNAIkena Oncology8.20x -- -- -$10.2M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 1.36% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.63% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.53% over the past day.
